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Background: Pre-existing antibodies to influenza virus neuraminidase may provide protection against infection
influenza viruses containing novel hemagglutinin (HA). The aim of our study was to evaluate serum
neuraminidase-inhibiting (NI) antibodies against А/California/07/2009(H1N1) [H1N1/2009pdm] and А/New
Caledonia/20/1999(H1N1) [H1N1/1999] influenza viruses in relation with the age of participants and
hemagglutination-inhibition (HI) antibody levels. Anti-H1N1/2009pdm neuraminidase and anti-H1N1/1999
neuraminidase antibody levels were measured in total 219 serum samples from Russian healthy peoples of
various ages examined before and a year after pandemic strain appearance. We adjusted peroxidase-linked lectin
micro-procedure to measure NI antibody titers using the reassortant A/H7N1 influenza viruses based on
A/equine/Prague/1/56(H7N7). Also, HI antibody titers were estimated against H1N1/2009pdm, H1N1/1999 and a
panel of seasonal A/H1N1 influenza viruses.
Results: In sera samples collected during the fall of 2010, mean titers of specific HI and NI antibodies to H1N1/
2009pdm were 2–2.1 times lower than antibody levels against H1N1/1999. Of the 163 individuals examined, 58
(35.6%) had NI anti-H1N1/2009pdm antibody titers > 1:20, compared to 93 (57.1%) who had NI anti-H1N1/1999
antibody titers > 1:20. There were low correlations between HI and NI antibody levels against either H1N1/1999 or
H1N1/2009pdm in the same serum samples. The 24 adults born between 1957 and 1977 expressed very low
levels of NI antibodies to A/H1N1 influenza viruses. Persons with low HI anti-H1N1/2009pdm titers but positive to
seasonal A/H1N1 demonstrated significantly higher NI anti-A/H1N1 antibody titers than unexposed subjects. In
2005 cross-reactive NI anti-H1N1/2009pdm antibody titers > 1:20 were detected among 7.1% of young people.
Conclusions: Our study confirmed that contact with seasonal influenza viruses may have contributed to
generating the cross-reacting anti-H1N1/2009pdm NI antibodies which were detected in the sera of 18-20 years
old people examined before the pandemic virus active circulation. The lowest levels of antibodies to the
neuraminidase of N1 subtype were in the group of participants born during the circulation of influenza A/H2N2
or A/H3N2 viruses. The low correlation between HI and NI antibody titers suggests that NI antibody detection can
be used as an additional test to evaluate the immune response after influenza infections or immunizations.
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In April 2009, the World Health Organization registered
the first 21st century pandemic caused by a type А/
H1N1 influenza virus (the genus Influenzavirus, the family
Orthomyxoviridae) not previously isolated from animals
or humans. Pandemic influenza, in contrast to seasonal
influenza, affected young people more frequently than
elderly [1]. In the USA, 79% of laboratory-confirmed cases
of pandemic H1N1/2009pdm infections were from per-
sons younger than 30 years, and 2% from age group older
than 60 years [2]. A number of publications have analyzed
pre-existing neutralizing antibodies and T-cell immunity
against H1N1/2009pdm [2,3], although little is known
about pre-existing cross-reactive anti-neuraminidase
(NA), or neuraminidase-inhibiting (NI) antibodies to
pandemic A/H1N1 in humans. Several animal studies,
including a plasmid DNA vaccine model, suggest that
NI antibodies could provide partial protection from
lung infection and even from lethal challenge with
highly pathogenic А/H5N1 influenza viruses [4-7].
In humans, NI antibodies play a role in decreasing the
severity of natural infection caused by influenza A shift
or drift variants [8]. Previously it was shown that
immunization with seasonal influenza strains induced
cross-reactive serum antibody to the NA of antigeni-
cally distinct H1N1/2009pdm, mostly in elderly indi-
viduals [9,10].
The aim of our current study was to examine the pres-
ence of homologous and cross-reactive NI antibodies
against H1N1/2009pdm in serum samples collected in
the fall of 2010 from healthy Russian people for more
detailed estimation of the overall and age-specific influ-
enza immunity.
Results and discussion
We estimated HI and NI antibodies against both H1N1/
2009pdm and seasonal H1N1/1999 influenza viruses in
163 sera samples obtained in the fall of 2010 (Figure 1).
Forty-four of the 163 individuals examined (27%) had HI




















Figure 1 Serum antibody titers against H1N1/1999 and H1N1/2009pd
neuraminidase-inhibition antibody titers against seasonal and pandemic A/
in the fall of 2010.had HI H1N1/1999 antibody titers > 1:20. Also, 93
(57.1%) of the participants expressed NI H1N1/1999 anti-
bodies in titers > 1:20, while only 58 (35.6%) expressed NI
H1N1/2009pdm antibodies in such titers (McNemar test:
p < 0.001).
From the 163 examined sera among 39.3% were de-
tected antibody titers > 1:20 against both HI and NI of
H1N1/1999; 6.7% and 17.8% expressed only HI or NI
antibodies against H1N1/1999 in such titers, respect-
ively. In comparison, 17.8% sera were double-positive to
both H1N1/2009pdm surface antigens; 9.2% and 17.8%
expressed only HI- or NI-antibodies against pandemic
strain in titers > 1:20, respectively. Chi-square test’s
p-value < 0.001 suggested a statistically significant re-
lationship between HI and NI antibody levels against
each A/H1N1 in the same serum samples, although
the correlation was rather low (Spearman rs = 0.32
[95% CI: 0.11–0.57], and rs = 0.29 [95% CI: 0.01–
0.54], in case of H1N1/1999 and H1N1/2009pdm
respectively). Forty-eight (29.5%) of subjects had NI
titers > 1:20 against both H1N1/1999 and H1N1/
2009pdm [95% CI: 23.0% –36.9%].
The age distribution of A/H1N1-specific antibodies
was analyzed in several age groups of participants.
Persons in group 1 were born prior to 1957; group 2:
1957–1976; group 3: 1977–1999; and group 4, after
2000 (Table 1). Only group 1 expressed NI antibodies
against H1N1/2009pdm in significantly higher mean ti-
ters than HI antibodies (Table 1). The highest mean ti-
ters of NI antibodies against both H1N1/2009pdm and
H1N1/1999 were detected in group 3.
Figure 2 presents the seroprotection rates (propor-
tions of subjects with antibody titers ≥ 1:40) [11]
among groups of participants. Again participants in
group 3 (1977–1999 years of birth) had the levels of
herd immunity to both HA and NA of seasonal
H1N1/1999 even higher than children born after 2000
(group 4), when А/New Caledonia/20/99(H1N1) be-
came dominant (Fisher’s test: p = 0.0001; see Figure 2).












m in the fall of 2010. Distribution of hemagglutination-inhibition and
H1N1 influenza viruses in serum samples collected from 163 volunteers
Table 1 Titers of antibodies against A/H1N1 influenza in volunteers of different ages examined in 2010
Groups Year of birth Antibodies against H1N1/2009pdm, log2 Antibodies against H1N1/1999, log2
HI titers, Me (Q1;Q3) NI titers, Me (Q1;Q3) HI titers, Me (Q1;Q3) NI titers, Me (Q1;Q3)
1 (n = 24) Before 1957 2.31 (2.3;2.3) 3.5 (2.3;5.3) 2.32 (2.3;2.8) 3.9 (2.3;5.1)
2 (n = 24) 1957–1976 2.3 (2.3;5.3) 2.33 (2.3;3.3) 2.3 (2.3;4.3) 3.8 (2.3;4.6)
3 (n = 78) 1977–1999 4.34 (3.3;5.3) 4.3 (3.4;5.3) 6.35 (5.3;8.3) 5.76 (4.8;6.4)
4 (n = 37) After 2000 2.3 (2.3;5.3) 2.9 (2.3;5.3) 2.3 (2.3;5.3) 3.4 (2.3;5.3)
Key: Me (medians), Q1; Q3 (lower and upper quartiles).
1Mean titers of HI antibodies against H1N1/2009pdm are lower than NI antibodies (p = 0.001).
2Mean titers of HI antibodies against H1N1/1999 are lower than NI antibodies (p = 0.006).
3Mean titers of antibodies against NA of pandemic influenza virus H1N1/2009pdm in are lower in group 2 than in group 3 (p = 0.002).
4Mean titers of HI antibodies against H1N1/2009pdm are higher in group 3 than in group 1 (p = 0.0002).
5Mean titers of HI antibodies against H1N1/1999 are higher in group 3 than in groups 1, 2, and 4 (p < 0.0001).
6Mean titers of NI antibodies H1N1/1999 are higher in group 3 than in groups 1, 2, and 4 (p < 0.001).
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dren, leading to more infections and development of
cross-reactive antibodies to previously circulating A/
H1N1 influenza viruses.
Participants born between 1957 and 1976 possessed
the lowest levels of NI antibodies against both H1N1/
1999 and H1N1/2009pdm influenza viruses (Table 1,
Figure 2).
To determine a possible origin of NI antibodies against
H1N1/2009pdm, we evaluated antibody titers ≥1:40 sup-
posed to be protective in three groups separated on the
basis of pre-existing HI antibody levels against H1N1/
2009pdm and seasonal A/H1N1 viruses (n = 159, 4 sera
were excluded from analysis because there was no HI
data with all tested A/H1N1 antigens). Group I were
persons with low HI titers (≤ 1:10) against H1N1/
2009pdm and no antibodies to other A/H1N1 viruses
(≤ 1:20); group II were persons with low HI titers (≤ 1:10)
against H1N1/2009pdm and positive (HI titers ≥ 1:40) for
any of the other tested A/H1N1 influenza viruses (see
Methods); and group III included all persons with HI
titers against H1N1/2009pdm ≥ 1:20 (Table 2). Group I
subjects, who were negative to all A/H1N1 viruses used in














































Figure 2 Hemagglutination-inhibition and neuraminidase-inhibition a
Seroprotection rates were defined as a percentage of subjects with titers≥
antibodies against H1N1/1999 or H1N1/2009pdm influenza viruses amongII (17 years) and group III (15 years), and a wider variation
of age (Kolmogorov-Smirnov’s test: p < 0.005; see Table 2).
Persons seropositive to seasonal A/H1N1 viruses but
with low HI titers against H1N1/2009pdm (group II) had
significantly higher NI titers against H1N1/2009pdm
than unexposed subjects from group I (p < 0.05). Two
adults from group II, aged 64 and 56 years, demonstrated
1:40 HI titers against А/Khabarovsk/1/77(H1N1) sea-
sonal influenza virus and NI antibodies against H1N1/
2009pdm in titers of 1:696 and 1:180, respectively. These
data suggest that exposure to seasonal A/H1N1 viruses
may induce cross-reactive NI antibodies against H1N1/
2009pdm in high titers. Nevertheless, group II contained
significantly fewer persons with NI antibody titers ≥ 1:40
against H1N1/2009pdm than against seasonal H1N1/
1999 (McNemar test: p < 0.001).
To reveal true cross-reactive NI antibodies against
H1N1/2009pdm, we also investigated levels of anti-
bodies against H1N1/2009pdm in serum samples col-
lected from 18–20-year-old people in the fall of 2005,
long before H1N1/2009pdm arose (Figure 3). None of
these subjects had detectable anti-H1N1/2009pdm HI
antibodies. Only 7.1% (4 of 56) had NI antibody titers
> 1:20 against H1N1/2009pdm compared to 41.1% (23Before 1957 1957-1976 1977-1999 After 2000
Years of birth
A/New Caledonia/20/99(H1N1)  
HI
NI
* p <0.001compared to other groups 




ntibodies seroprotection rates in dependence of birth date.
1:40 of hemagglutination-inhibition and neuraminidase-inhibition
163 individuals examined in the fall of 2010.
Table 2 Homologous and cross-reactive antibodies against NA of H1N1/2009pdm among participants examined in 2010





Antibodies to H1N1/2009pdm Antibodies to H1N1/1999
HI titers, log2 NI titers, log2 HI titers, log2 NI titers, log2
H1N1/2009pdm seasonal A/H1N1 viruses Me (Q1;Q3) % ≥ 1:40 Me (Q1;Q3) % ≥ 1:40 Me (Q1;Q3) % ≥ 1:40 Me (Q1;Q3) % ≥ 1:40
I ≤1:10 ≤ 1:20 45 (6; 58) 2.3 (2.3;2.3) 0 2.3 (2.3;3.2) 2.4 2.3(2.3; 2.3) 0 2.3 (2.3; 4.1) 2.4
N = 41
II ≤1:10 ≥ 1:40 17 (10; 26) 2.31 (2.3; 3.3) 0 3.42 (2.3; 4.3) 15.7 6.2(4.3; 8.3) 72.5 5.3 (4.1; 6.2) 51.03
N = 51
III ≥ 1:20 any 15 (12; 20) 5.3 (4.3; 6.3) 65.7 5.24 (3.9; 5.6) 38.8 5.3(2.3; 7.3) 56.7 5.5 (3.9; 6.4) 55.2
N = 67
Key: N (number), Me (medians), Q1; Q3 (lower and upper quartiles); % (percent).
1Titers of HI antibodies against H1N1/2009pdm are similar in group I and group II (Dunn’s test: z’ = 0.959, p = 1.0).
2Titers of NI antibodies H1N1/2009pdm are higher in group II than in group I (Dunn’s test: z′ = 2.421, p = 0.046).
3In group II, percentage of volunteers with antibody titers ≥ 1:40 to NA of seasonal H1N1/1999 higher than to NA of H1N1/2009pdm (McNemar test: p < 0.001).
































































Figure 3 Serum antibodies against A/H1N1 influenza viruses during 2005 and 2010 flu seasons. Percentage of seropositive 18–20-year-old
persons with titers > 1:20 of hemagglutination-inhibition and neuraminidase-inhibition antibodies against seasonal and pandemic A/H1N1 influenza
viruses; * indicates p < 0.001, McNemar test.
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H1N1/1999 (McNemar test: p < 0.001). In contrast,
34.3% (12 of 35) of samples collected from young
adults of the same age in 2010 contained HI anti-
bodies in titers > 1:20 against H1N1/2009pdm, and
45.7% (16 of 35) participants demonstrated NI anti-
bodies to pandemic virus in titers > 1:20.
A year after the pandemic A/H1N1 virus first emerged
in Russian population the mean titers of specific HI and
NI antibodies against H1N1/2009pdm in all examined
volunteers were 2–2.1 times lower than levels of anti-
bodies against H1N1/1999, which circulated in Russia
1999–2006. Likewise Cramer et al. [12] previously re-
ported that in 2010 the threshold level of herd immunity
against H1N1/2009pdm was not achieved in Hamburg,
Germany.
In our study, the participants born between 1977 and
1999 were the most likely to be infected to pandemic
H1N1/2009pdm compared to those born before 1957.
This finding confirmed the extensive published data
about the high frequency of H1N1/2009pdm infection in
children, teenagers, and adults younger than 35 years
during the 2009 pandemic, varying between 20–60% in
different countries [13]. High anti-H1N1/2009pdm NA
antibody levels, rather than anti-HA antibody levels, in
participants older than 53 years can be attributed to
contact with earlier circulating A/H1N1 viruses. Examin-
ing ages of persons with no antibodies against H1N1/
2009pdm HA (HI titers ≤ 1:10), we found anti-H1N1/
2009pdm NA antibodies in titers ≥ 1:40 in 22.7% (5 of
22), 12.9% (4 of 31), and 3.8% (1 of 26) of participants
born before 1957, in 1977–1999, and after 2000, respect-
ively, but none in persons born between 1957 and 1977.
Thus, in our study differences in levels of anti-H1N1/
2009pdm NA antibodies in people without direct con-
tact with pandemic virus depended on age and, possibly,
on priming by previous epidemic influenza viruses.
Indeed, volunteers born in 1957–1976, when influenza
viruses A/H2N2 and A/H3N2 were circulating, were the
least likely to have anti-H1N1/2009pdm NA antibody
titers ≥ 1:40, but about one third of participants fromthis age group had anti-H1N1/2009pdm HI antibody
titers ≥ 1:40 (Figure 2), most likely due to pandemic virus
natural infection.
The low correlation between HI and NI antibody titers
we found can be attributed to the autonomy of the
serum immune response to both surface glycoproteins
of the influenza virus, widely reviewed in scientific litera-
ture [14-16]. Other reasons for such divergence may be
different times of persistence of NI and HI antibodies,
according to individual anamnesis of the surveyed influ-
enza infections [17,18], and the ability of anti-NA anti-
bodies to interact with a wider spectrum of viruses than
anti-HI antibodies. Thus, some persons with no anti-
bodies against HA of influenza pandemic virus in the fall
of 2010 still may have been exposed to H1N1/2009pdm.
Nevertheless, high levels of antibodies against H1N1/
2009pdm NA among participants not expressing anti-
H1N1/2009pdm HA of pandemic virus, but positive to
epidemic H1N1 viruses HA, compared with completely
negative individuals examined during the same epidemic
period, may, to some extent, confirm the relationship
between exposure to epidemic A/H1N1 viruses and
development of antibodies cross-reactive with H1N1/
2009pdm NA. However, the most reliable data about
truly cross-reactive antibodies to H1N1/2009pdm may
be obtained using sera collected long before the ap-
pearance of pandemic virus. During the 2005 epidemic
season, the 7.1% of the 56 examined in our study 18–
20-year-old volunteers had anti-pandemic virus NI
antibodies in titers > 1:20.
The most convincing data concerning the protective
action of pre-existing anti-NA antibodies were obtained
in the 1970s using a large cohort of volunteers with no
or low levels of anti-HA antibodies against pandemic
influenza. One such study, by Monto et al. [8], showed
that, prior to the Hong Kong A/H3N2 influenza pan-
demic, only 12% of the population had high NI antibody
titers to NA of N2 subtype, while 72% had none. The
relatively low level of herd immunity to A/H2N2 NA in
the population correlated with the wide distribution of
the new pandemic subtype A/H3N2 virus in 1968.
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to moderate the severity of the pandemic: the frequency
of confirmed A/H3N2 influenza infection, determined
by elevated levels of HI antibodies, was reversely propor-
tional to pre-existing levels of anti-N2 antibodies. The
possible effect of HA was eliminated because the sera
were obtained before the virus with the novel H3 HA
had appeared. Volunteers between 20 and 45 years of
age who had anti-N2 antibodies in titers ≥ 1:16 were
2.0–2.6-fold less likely to develop respiratory infection
symptoms than persons with low NI antibody titers. The
authors suggested that neuraminidase antibody can pro-
tect not so much against infection as against symptoms
of influenza thus permitting the individual to ‘up-date’
his antibody status from time to time without suffering
clinical influenza [8]. The levels of protective NI anti-
bodies still unclear although protective HI antibody ti-
ters defined as ≥ 1:40 [11]. The results of several studies
suggest the different levels of NI antibodies obtained in
several laboratories (1:8- ≥ 1:20) may be protective
against natural influenza infection [8,18,19].Conclusions
Our study confirmed that contact with seasonal influ-
enza viruses may have contributed to generating the
cross-reacting antibodies against NA of H1N1/2009pdm.
Indeed, сross-reactive anti-H1N1/2009pdm NA present
in the sera of individuals negative to pandemic virus
HA, but positive to epidemic strains of A/H1N1 subtype.
NI antibodies against the pandemic virus were detected
among 7.1% of volunteers 18-20 years old examined in
2005, several years before this virus actually broke out.
The lowest levels of antibodies to the NA of N1 subtype
belonging to either H1N1/2009pdm or H1N1/1999 were
in the group of participants 1957-1977 years of birth, i.e.
born during the circulation of influenza A/H2N2 or A/
H3N2 viruses.
The low correlation between HI and NI antibody titers
we found suggests that NI antibody detection can be
used as an additional test to evaluate the immune re-
sponse after influenza infections or immunizations.Methods
Viruses
The A/H7N1 reassortant influenza virus containing A/
California/07/2009(H1N1) NA and A/equine/Prague/1/
56(H7N7) HA was generated by classical genetic reas-
sortment in embryonated chicken eggs [20]. Parental
A/equine/Prague/1/56(H7N7) influenza virus was kindly
provided by Dr. Klimov at the CDC (Atlanta, GA, USA).
The other A/H7N1 reassortant influenza virus containing
А/New Caledonia/20/1999(H1N1) NA and A/equine/
Prague/1/56(H7N7) HA was provided by the Institute ofInfluenza, Ministry of Healthcare of the Russian Feder-
ation, Saint Petersburg, Russian Federation.Serum samples
163 sera were collected in the fall of 2010 from Russian
people aged 2–83 years. Patient history regarding previ-
ous influenza infections or vaccinations was unknown.
These serum samples left as part of routine tests. We
also tested 56 sera left as part of screening tests of young
adults examined before vaccination with seasonal influ-
enza vaccine in the fall of 2005.Ethics statement
In our retrospective study we used only serum samples
left as a part of routine tests. These serum samples
were provided by the Diagnostics Laboratories (Saint
Petersburg, Russian Federation).Serum antibody evaluation
Sera were treated with receptor-destroying enzyme from
Vibrio cholerae (Denka-Seiken, Tokyo, Japan), and tested
in duplicate for hemagglutination-inhibition H1-specific
antibodies using standard procedures [21] with the
following test antigens: live influenza vaccine viruses А/
17/California/09/38(H1N1), А/17/New Caledonia/99/
145(H1N1), А/17/Solomon Islands/06/9(H1N1), А/17/
Brisbane/07/28(H1N1); seasonal influenza virus 1977 year
of isolation А/Khabarovsk/1/77(H1N1) and А/Puerto
Rico/8/34(H1N1).
The peroxidase-linked lectin micro-procedure previ-
ously reported by Lambré et al. [22] was adjusted to
assay NI antibodies using diagnostic A/H7N1 reassor-
tant viruses. Serum samples were heated at 56°C for
30 min, serially diluted in PBS-BSA with the pH = 6.9
(typically, seven 2-fold dilutions starting at 1:10). Sixty
μL of serum dilutions were incubated with an equal
volume of pre-diluted virus containing 128 HA units for
30 min at 37°C. After incubation, 100 μL of the mixture
was added to the 96-well plates (Sarstedt AG & Co,
Nümbrecht, Germany) coated with 150 μL of 50 μg/mL
fetuin (Sigma-Aldrich, St. Louis, MO, USA). After 2 hours
incubation at 37°C the plates were washed, and NA
activity was measured by incubating with peroxidase-
labeled peanut lectin (2.5 μg/mL; Sigma-Aldrich, St.
Louis, MO, USA) for 1 h at room temperature, wash-
ing, and adding 100 μL of peroxidase substrate. The
reaction was stopped after 5 min with 100 μL of 1 N
sulfuric acid. OD values were measured at 450 nm
using the universal microplate reader (ELx800, Bio-Tek
Instruments Inc, Winooski, VT, USA). NI titers were
expressed as the inverse of the dilution that gave 50%
OD450 of positive control (virus without serum).
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Data were analyzed with Statistica software, version 6.0
(StatSoft, Inc. Tulsa, Oklahoma, USA). Medians (Me)
and lower and upper quartiles (Q1; Q3) were calculated
and used to represent the antibody response. Compari-
sons of two independent groups were made with
nonparametric test, namely the Kolmogorov-Smirnov
2-sample test. To compare multiple independent groups,
we used a Kruskal-Wallis analysis of variance (ANOVA)
with subsequent multiple pairwise comparisons based on
Kruskal-Wallis sums of ranks. Comparisons of two
dependent variables were performed using Wilcoxon
matched pairs test. In the case of nominal variables, Chi-
square tests, Fisher exact 2-tailed tests, or McNemar’s
chi-square tests were done. Non-parametric measure of
statistical dependence between 2 variables was done
using Spearman’s rank correlation coefficient. The p-
value ≤ 0.05 was considered to be statistically significant.
Additionally, we used the Bonferroni correction for
significance levels when testing several hypotheses on a
single set of data.
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